CORDIS
EU research results

CORDIS

English EN
Liver Investigation: Testing Marker Utility in Steatohepatitis

Liver Investigation: Testing Marker Utility in Steatohepatitis

Objective

Strongly associated with the epidemics of obesity and type 2 diabetes that are testing healthcare systems worldwide, Non-Alcoholic Fatty Liver Disease (NAFLD) is an increasingly common cause of advanced liver disease that is characterized by substantial inter-patient variability in severity and rate of progression. It is currently assessed by liver biopsy, an invasive, costly and risky procedure. The lack of noninvasive biomarkers has hampered patient care and impeded drug development by complicating conduct of clinical trials.The overarching aim of LITMUS is to develop, robustly validate and advance towards regulatory qualification biomarkers that diagnose, risk stratify and/or monitor NAFLD/NASH progression and fibrosis stage. This will be achieved through a goal-oriented, tri-partite collaboration delivering a definitive and impartial evaluation platform for biomarkers, bringing together: (i) End-users of biomarker technologies (clinicians with expertise in NAFLD and the pharmaceutical industry)? (ii) Independent academics with expertise in the evaluation of medical test/biomarker performance? and (iii) Biomarker researchers and developers (academic or commercial).

LITMUS has the demonstrable capability to fulfil the IMI call remit. Built upon foundations laid by the EU-funded FLIP/EPoS projects and long-established, successful scientific collaborations amongst many of Europe’s leading clinical-academic centres, LITMUS is at a unique advantage due to its existing large-scale patient cohorts, bioresources and multi-omics datasets. Consortium members are internationally recognised experts with substantial relevant expertise supporting the program’s clear focus on biomarker identification, validation and accelerating EMA/FDA qualification. Thus, LITMUS is powered to provide clarity on biomarker validity for NAFLD at scale and pace: supporting drug development and the targeting of medical care and limited healthcare resources to those at greatest need.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITY OF NEWCASTLE UPON TYNE

Address

Kings Gate
Ne1 7ru Newcastle Upon Tyne

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 897 911,25

Participants (53)

Sort alphabetically

Sort by EU Contribution

Expand all

Academisch Medisch Centrum bij de Universiteit van Amsterdam

Netherlands

EU Contribution

€ 1 180 910

INST CARDIOMETABOLISME NUTRITION ICAN

France

EU Contribution

€ 684 250

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

France

EU Contribution

€ 260 500

UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ

Germany

EU Contribution

€ 1 073 015

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 638 130

OREBRO UNIVERSITY

Sweden

EU Contribution

€ 312 500

ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS

Spain

EU Contribution

€ 403 017,50

UNIVERSITAET BERN

Switzerland

EU Contribution

€ 435 000

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 1 818 750

PERSPECTUM DIAGNOSTICS LTD

United Kingdom

EU Contribution

€ 250 000

SERVICIO ANDALUZ DE SALUD

Spain

EU Contribution

€ 601 250

NORDIC BIOSCIENCE A/S

Denmark

EU Contribution

€ 1 427 093

NORDIC BIOSCIENCE COMPOUND DEVELOPMENT A/S

Denmark

LUXEMBOURG INSTITUTE OF HEALTH

Luxembourg

EU Contribution

€ 540 033,75

UNIVERSITA DEGLI STUDI DI TORINO

Italy

EU Contribution

€ 365 160,75

UNIVERSITE D'ANGERS

France

EU Contribution

€ 122 500

UNIVERSITAIR ZIEKENHUIS ANTWERPEN

Belgium

EU Contribution

€ 167 100

LINKOPINGS UNIVERSITET

Sweden

EU Contribution

€ 99 600

HELSINGIN YLIOPISTO

Finland

EU Contribution

€ 202 500

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

Netherlands

EU Contribution

€ 273 328,75

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON

Greece

EU Contribution

€ 118 350

FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA

Portugal

EU Contribution

€ 78 487,50

UNIVERSITA DEGLI STUDI DI MILANO

Italy

EU Contribution

€ 80 722,50

UNIVERSITA DEGLI STUDI DI PALERMO

Italy

EU Contribution

€ 105 081,25

UNIVERSITA CATTOLICA DEL SACRO CUORE

Italy

EU Contribution

€ 80 653,75

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT

Germany

EU Contribution

€ 406 206,25

UNIVERSITAETSKLINIKUM AACHEN

Germany

EU Contribution

€ 248 076,25

THE UNIVERSITY OF NOTTINGHAM

United Kingdom

EU Contribution

€ 118 115

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 54 075

ANTAROS MEDICAL AB

Sweden

EU Contribution

€ 231 275

THE UNIVERSITY OF BIRMINGHAM

United Kingdom

EU Contribution

€ 61 263,75

IXSCIENT LIMITED

United Kingdom

EU Contribution

€ 344 375

Faculdade de Farmácia da Universidade de Lisboa

Portugal

EU Contribution

€ 56 968,75

EUROPEAN ASSOCIATION FOR THE STUDYOF THE LIVER

Switzerland

EU Contribution

€ 61 680

GENFIT

France

INTERCEPT PHARMA EUROPE LTD

United Kingdom

ONE WAY LIVER SL

Spain

EU Contribution

€ 1

EXALENZ BIOSCIENCE LTD

Israel

Eli Lilly and Company Limited

United Kingdom

PFIZER LIMITED

United Kingdom

BOEHRINGER INGELHEIM INTERNATIONALGMBH

Germany

SOMALOGIC INC

United States

NOVO NORDISK A/S

Denmark

SANOFI-AVENTIS DEUTSCHLAND GMBH

Germany

ELLEGAARD GOTTINGEN MINIPIGS AS

Denmark

NOVARTIS PHARMA AG

Switzerland

TAKEDA DEVELOPMENT CENTRE EUROPE LTD.

United Kingdom

ASTRAZENECA AB

Sweden

ECHOSENS

France

RESOUNDANT, INC.

United States

BRISTOL-MYERS SQUIBB COMPANY CORP

United States

HISTOINDEX PTE LTD

Singapore

ALLERGAN LIMITED

United Kingdom

Project information

Grant agreement ID: 777377

Status

Ongoing project

  • Start date

    1 November 2017

  • End date

    31 October 2022

Funded under:

H2020-EU.3.1.7.13.

  • Overall budget:

    € 46 461 776,13

  • EU contribution

    € 15 797 881

Coordinated by:

UNIVERSITY OF NEWCASTLE UPON TYNE

United Kingdom